{"title":"原发性斯约格伦综合征患者的血清转甲状腺素水平和疾病活动性。","authors":"You-Fan Peng, Fei-Yan Lu, Yi-Bin Deng","doi":"10.1177/1759720X241283528","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A strong association has been demonstrated between serum transthyretin (TTR) levels and autoimmune diseases. However, there is limited information regarding the role of serum TTR in patients with primary Sjögren's syndrome (pSS).</p><p><strong>Objectives: </strong>This study was designed to explore the association between serum TTR and disease activity in patients with pSS.</p><p><strong>Design: </strong>This study was a retrospective observational study.</p><p><strong>Methods: </strong>This study included 84 patients with pSS and 135 age- and sex-matched healthy controls retrospectively, and collected data were analyzed. The European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and Clinical ESSDAI (ClinESSDAI) scores were used to assess the disease activity in patients with pSS.</p><p><strong>Results: </strong>Serum TTR levels were significantly lower in patients with pSS than those in healthy controls (181.9 ± 69.2 vs 241.8 ± 48.9 mg/L, <i>p</i> < 0.001). Serum TTR levels were significantly and negatively correlated with ESSDAI (<i>r</i> = -0.385, <i>p</i> < 0.001) and ClinESSDAI (<i>r</i> = -0.340, <i>p</i> = 0.002) scores in patients with pSS, respectively. Multivariable linear regression analysis showed that serum TTR was significantly associated with ESSDAI (Beta = -0.248, <i>p</i> = 0.017) and ClinESSDAI (Beta = -0.215, <i>p</i> = 0.036) scores in patients with pSS, respectively.</p><p><strong>Conclusion: </strong>Serum TTR is a potential marker for assessing disease activity in patients with pSS, which may contribute to the clinical management of pSS.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483703/pdf/","citationCount":"0","resultStr":"{\"title\":\"Serum transthyretin levels and disease activity in patients with primary Sjögren's syndrome.\",\"authors\":\"You-Fan Peng, Fei-Yan Lu, Yi-Bin Deng\",\"doi\":\"10.1177/1759720X241283528\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>A strong association has been demonstrated between serum transthyretin (TTR) levels and autoimmune diseases. However, there is limited information regarding the role of serum TTR in patients with primary Sjögren's syndrome (pSS).</p><p><strong>Objectives: </strong>This study was designed to explore the association between serum TTR and disease activity in patients with pSS.</p><p><strong>Design: </strong>This study was a retrospective observational study.</p><p><strong>Methods: </strong>This study included 84 patients with pSS and 135 age- and sex-matched healthy controls retrospectively, and collected data were analyzed. The European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and Clinical ESSDAI (ClinESSDAI) scores were used to assess the disease activity in patients with pSS.</p><p><strong>Results: </strong>Serum TTR levels were significantly lower in patients with pSS than those in healthy controls (181.9 ± 69.2 vs 241.8 ± 48.9 mg/L, <i>p</i> < 0.001). Serum TTR levels were significantly and negatively correlated with ESSDAI (<i>r</i> = -0.385, <i>p</i> < 0.001) and ClinESSDAI (<i>r</i> = -0.340, <i>p</i> = 0.002) scores in patients with pSS, respectively. Multivariable linear regression analysis showed that serum TTR was significantly associated with ESSDAI (Beta = -0.248, <i>p</i> = 0.017) and ClinESSDAI (Beta = -0.215, <i>p</i> = 0.036) scores in patients with pSS, respectively.</p><p><strong>Conclusion: </strong>Serum TTR is a potential marker for assessing disease activity in patients with pSS, which may contribute to the clinical management of pSS.</p>\",\"PeriodicalId\":23056,\"journal\":{\"name\":\"Therapeutic Advances in Musculoskeletal Disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483703/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Musculoskeletal Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1759720X241283528\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720X241283528","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Serum transthyretin levels and disease activity in patients with primary Sjögren's syndrome.
Background: A strong association has been demonstrated between serum transthyretin (TTR) levels and autoimmune diseases. However, there is limited information regarding the role of serum TTR in patients with primary Sjögren's syndrome (pSS).
Objectives: This study was designed to explore the association between serum TTR and disease activity in patients with pSS.
Design: This study was a retrospective observational study.
Methods: This study included 84 patients with pSS and 135 age- and sex-matched healthy controls retrospectively, and collected data were analyzed. The European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and Clinical ESSDAI (ClinESSDAI) scores were used to assess the disease activity in patients with pSS.
Results: Serum TTR levels were significantly lower in patients with pSS than those in healthy controls (181.9 ± 69.2 vs 241.8 ± 48.9 mg/L, p < 0.001). Serum TTR levels were significantly and negatively correlated with ESSDAI (r = -0.385, p < 0.001) and ClinESSDAI (r = -0.340, p = 0.002) scores in patients with pSS, respectively. Multivariable linear regression analysis showed that serum TTR was significantly associated with ESSDAI (Beta = -0.248, p = 0.017) and ClinESSDAI (Beta = -0.215, p = 0.036) scores in patients with pSS, respectively.
Conclusion: Serum TTR is a potential marker for assessing disease activity in patients with pSS, which may contribute to the clinical management of pSS.
期刊介绍：
Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
